# US 2019/0314389 A1 · Compositions comprising triterpenoids

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0314389 A1
- Document ID: US20190314389A1
- Status: Published application
- Kind: A1
- Application number: 16/451,621
- Filed: 2019-06-25
- Published: 2019-10-17
- Earliest claimed: 2015-09-24
- Assignees: Regenera Pharma Ltd.
- Applicants: Regenera Pharma Ltd.
- Inventors: Zadik HAZAN; Konstantin ADAMSKY; Andre C. B. LUCASSEN; Nurit NOVAK
- Web page: https://patentgrep.com/patent/US20190314389A1

## CPC

- A61K 31/575: substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
- A61K 31/047: having two or more hydroxy groups, e.g. sorbitol
- A61K 31/122: having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A61K 31/56: Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K 31/569: substituted in position 17 alpha, e.g. ethisterone
- A61K 31/745: Polymers of hydrocarbons
- A61K 36/22: Anacardiaceae (Sumac family), e.g. smoketree, sumac or poison oak
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to compositions and formulations comprising at least one triterpenoic acid and at least one neutral triterpenoid and uses thereof for treating stroke or trauma and side effects related thereto.

## Claims

### Claim 1

A method of treating a stroke or trauma, the method comprising administering to a subject in need thereof a pharmaceutical composition comprising a combination of at least one triterpenoic acid and at least one neutral triterpenoid, and a pharmaceutically acceptable carrier, wherein the triterpenoic acid is selected from masticadienonic acid (MDA), isomasticadienonic acid (IMDA), or both, and wherein the neutral triterpenoid is selected from (8R)-3-beta, 8-dihydroxypolypoda-13E,17E,21-triene (NF-1), (8R)-3-Oxo-8-hydroxypolypoda-13E,17E,21-triene (NF-2), or both.

### Claim 2 (depends on 1)

The method according to claim 1, further comprising at least one additional triterpenoic acid selected from the group consisting of: masticadienolic acid (MLA), isomasticadienolic acid (IMLA), 3-O-acetyl masticadienolic acid, 3-O-acetyl epimasticadienolic acid, 3-O-acetyl isomasticadienolic acid, 3-O-acetyl epi-isomasticadienolic acid, oleanonic acid (OA), moronic acid (MA), or any combination thereof.

### Claim 3 (depends on 1)

The method according to claim 1, further comprising at least one additional neutral triterpenoid selected from the group consisting of Oleanonic aldehyde (NF-3), Tirucallol (NF-4), 28-hydroxylup-20(29)-en-3-one (NF-A), 28-hydroxy-beta-amyrone (NF-B), or any combination thereof.

### Claim 4 (depends on 3)

The method according to claim 3, further comprising 20-hydroxydammar-24-en-3-one (NF-P).

### Claim 5 (depends on 3)

The method according to claim 3, wherein at least one of said additional neutral triterpenoids is selected from NF-3 and NF-4.

### Claim 6 (depends on 3)

The method according to claim 3, comprising at least two additional neutral triterpenoids.

### Claim 7 (depends on 1)

The method according to claim 1, substantially devoid of essential oils.

### Claim 8 (depends on 1)

The method according to claim 1, wherein at least one triterpenoic acid is obtained from a plant source.

### Claim 9 (depends on 1)

The method according to claim 1, wherein at least one neutral triterpenoid is obtained from a plant source.

### Claim 10 (depends on 8)

The method according to claim 8, wherein said plant source comprises mastic gum.

### Claim 11 (depends on 1)

The method according to claim 1, wherein at least one triterpenoic acid is obtained via chemical synthesis.

### Claim 12 (depends on 1)

The method according to claim 1, wherein at least one neutral triterpenoid is obtained via chemical synthesis.

### Claim 13 (depends on 1)

The method according to claim 1, wherein said pharmaceutically acceptable carrier comprises at least one oil.

### Claim 14 (depends on 1)

The method according to claim 1, in a form suitable for administration by a route selected from the group consisting of parenteral, transdermal, oral and topical.

### Claim 15 (depends on 3)

The method according to claim 3, comprising pharmaceutically active ingredients consisting essentially of: MA, OA, MDA, IMDA, 3-O-acetyl masticadienolic acid, 3-O-acetyl isomasticadienolic acid, NF-1, NF-2, NF-3, NF-4, NF-A and NF-B; and the pharmaceutically acceptable carrier.

### Claim 16 (depends on 3)

The method according to claim 3, comprising pharmaceutically active ingredients consisting essentially of: MA, OA, MDA, IMDA, 3-O-acetyl masticadienolic acid, 3-O-acetyl isomasticadienolic acid, NF-1, NF-2, NF-3 and NF-4; and the pharmaceutically acceptable carrier.

### Claim 17 (depends on 3)

The method according to claim 3, comprising pharmaceutically active ingredients consisting essentially of: OA, MDA, IMDA, 3-O-acetyl masticadienolic acid, 3-O-acetyl isomasticadienolic acid, NF-1, NF-2, NF-3, NF-4, NF-A and NF-B; and a pharmaceutically acceptable carrier.

### Claim 18 (depends on 3)

The method according to claim 3, comprising pharmaceutically active ingredients consisting essentially of: OA, MDA, IMDA, 3-O-acetyl masticadienolic acid, 3-O-acetyl isomasticadienolic acid, NF-1, NF-2, NF-3 and NF-4; and a pharmaceutically acceptable carrier.

### Claim 19 (depends on 4)

The method according to claim 4, comprising pharmaceutically active ingredients consisting essentially of: MDA, IMDA, MLA, IMLA, NF-1, NF-2, NF-3, NF-4, NF-P, NF-A and NF-B; and a pharmaceutically acceptable carrier.

### Claim 20 (depends on 3)

The method according to claim 3, comprising pharmaceutically active ingredients consisting essentially of: MDA, IMDA, NF-1, NF-2, NF-3 and NF-4; and the pharmaceutically acceptable carrier.

### Claim 21 (depends on 1)

The method according to claim 1, comprising pharmaceutically active ingredients consisting essentially of: of MDA, IMDA, NF-1, NF-2; and the pharmaceutically acceptable carrier.

### Claim 22 (depends on 1)

The method according to claim 1, wherein treating a stroke or trauma comprises treating side effects related thereto.

### Claim 23 (depends on 22)

The method according to claim 22, wherein the trauma is a traumatic brain injury (TBI).
